Andrew Rowland

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 22

Top Venues

Clinical and translational science

British journal of clinical pharmacology

Pharmaceutics

JCO precision oncology

Flinders University

Flinders University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Flinders University Jul 11 2011

Australia

Senior Lecturer :: Clinical Pharmacology

Education History

Flinders University - Dec 16 2009

Australia

PHD :: Clinical Pharmacology

Publications

Lauren A Newman, Zivile Useckaite, Ting Wu, Michael J Sorich, Andrew Rowland
Establishing the capacity to monitor proteins relevant to the study of drug exposure and response using liver-derived extracellular vesicles. British journal of clinical pharmacology (2024)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science (2023)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science (2023)
Radwan Ansaar, Robyn Meech, Andrew Rowland
A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution. Pharmaceutics 15 (4) (2023)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science (2023)
Radwan Ansaar, Robyn Meech, Andrew Rowland
A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution. Pharmaceutics 15 (4) (2023)
Radwan Ansaar, Robyn Meech, Andrew Rowland
A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution. Pharmaceutics 15 (4) (2023)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science 17 (1) (2023)
Ashley M Hopkins, Michael J Sorich, Andrew J McLachlan, Christos S Karapetis, John O Miners, Madelé van Dyk, Andrew Rowland
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer. JCO precision oncology 7 (2023)
Ashley M Hopkins, Michael J Sorich, Andrew J McLachlan, Christos S Karapetis, John O Miners, Madelé van Dyk, Andrew Rowland
Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer. JCO precision oncology 7 (2023)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science 17 (1) (2023)
Radwan Ansaar, Robyn Meech, Andrew Rowland
A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution. Pharmaceutics 15 (4) (2023)
Zivile Useckaite, Lauren A Newman, Ashley M Hopkins, Sonja Klebe, Alex D Colella, Nusha Chegeni, Ruth Williams, Michael J Sorich, A David Rodrigues, Tim K Chataway, Andrew Rowland
Proteomic profiling of paired human liver homogenate and tissue derived extracellular vesicles. Proteomics (2023)
Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren A Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy. Clinical and translational science 17 (1) (2023)
Lauren A Newman, Kate Muller, Andrew Rowland
Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases. Cellular and molecular life sciences : CMLS 79 (5) (2022)
Elise M Newman, Andrew Rowland
A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure. International journal of molecular sciences 23 (19) (2022)
Jessica M Logan, Douglas A Brooks, Andrew Rowland, Michael J Sorich, Ashley M Hopkins
Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. Journal of oncology 2021 (2021)
Andrew Rowland, Madelé van Dyk, Ashley M Hopkins, Reham Mounzer, Thomas M Polasek, Amin Rostami-Hodjegan, Michael J Sorich
Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure. Clinical pharmacology and therapeutics 104 (6) (2018)
Thomas M Polasek, Geoffrey T Tucker, Michael J Sorich, Michael D Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera, Andrew Rowland
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British journal of clinical pharmacology 84 (3) (2018)
Andrew Rowland, Warit Ruanglertboon, Madelé van Dyk, Dhilushi Wijayakumara, Linda S Wood, Robyn Meech, Peter I Mackenzie, A David Rodrigues, Jean-Claude Marshall, Michael J Sorich
Plasma extracellular nanovesicle (exosome)-derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure. British journal of clinical pharmacology 85 (1) (2018)
Angela Rowland, Madelé van Dyk, David Warncken, Arduino A Mangoni, Michael J Sorich, Andrew Rowland
Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. British journal of clinical pharmacology 84 (3) (2018)
John O Miners, Attarat Pattanawongsa, Andrew Rowland
Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin. British journal of clinical pharmacology 84 (2) (2017)

Andrew Rowland.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Andrew Rowland